Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Olea Europaea Pollen

Inclusion Criteria: * Prior to study specific examinations the patient and if applicable both legal guardians has to give his/her written informed consent * Patients of both gender aged from 18 and 55 years * Patient's perception of disease activity of at least 30 mm on a 100 mm visual analogue scale (VAS) * FEV1 greater or equal than 80% of the expected value, and if not, improvement of FEV1 greater than 12% after bronchodilation * Patients have to suffer from allergic complaints (rhinitis and/or rhinoconjunctivitis with or without mild intermittent allergic asthma) caused by clinical sensitization against Olea europaea pollen. The IgE mediated sensitization has to be verified by: * Suggestive medical history * Specific IgE against Olea europaea pollen CAP RAST ≥0.7Ku/l * Positive skin prick test (SPT) to grass Olea pollen resulting in a wheal diameter of at least 3 mm. Exclusion Criteria * History of significant clinical manifestations of allergy as a result of sensitization against weed pollen allergens and perennial (e.g. house dust mite. * Participation in an immunotherapy with comparable extracts within the last five years. * Treatment with β-blocker * Any disease which prohibits the use of adrenaline (e.g. hyperthyroidism) * Cardiovascular insufficiency or any severe or unstable pulmonary, or endocrine disease; clinically significant renal or hepatic disease or dysfunction; hematologic disorder; any other clinically significant medical condition that could increase the risk to the study participant * Immunopathological diseases * Patients who are expected to be non-compliant and/or not co-operative * Women, where pregnancy is defined as the state of a female after conception and until the termination of gestation